Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 613

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 613
---
 cumulative revenue, is also recognized over the performance period based on a similar method. Where Kineta has no remaining performance obligations, revenue from such milestones is recognized when the accomplishment of the milestones is deemed probable.

Kineta expects that any revenue generated from its current collaboration, research and license agreements and any future collaboration partners will fluctuate from year to year as a result of the timing and number of milestones and other payments.

Collaboration Revenues

In connection with the Kineta-Yumanity Merger, Kineta became the successor in interest to an exclusive license and research collaboration agreement (the “Merck Neuromuscular License Agreement”) with Merck (known as MSD outside the United States and Canada) to support research, development and commercialization of products for treatment of neuromuscular diseases, including amyotrophic lateral sclerosis. Kineta recognizes revenue using the cost-to-cost method, which Kineta believe best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recognized as a percentage of actual cost incurred to the estimated costs to complete.**

<div align='center'>394</div>

Operating Expenses Research and Development Expenses Research and development expenses represent costs incurred in connection with the discovery, research, preclinical and clinical development, and manufacture of Kineta’s product candidates. Kineta recognizes all research and development costs as they are incurred. Research and development expenses consist primarily of the following:

| • |     | salaries, bonuses, benefits, stock-based compensation, research and consulting arrangements and other related costs for individuals involved in research and development activities; |

| • |     | external research and development expenses incurred under agreements with contract research organizations, investigative sites and other scientific development services; |

| • |     | costs incurred under agreements with contracted research and manufacturing organizations for developing and manufacturing materials for preclinical studies, clinical trials and laboratory supplies; |

| • |     | licensing agreements and associated costs; |

| • |     | costs related to compliance with regulatory requirements; |

| • |     | facilities and other allocated expenses for rent and insurance; and |

| • |     | other expenses incurred to advance research and development activities including manufacturing costs associated with production, scale up, testing and optimization of methods associated with the production of materials. |

**The largest component of Kineta’s operating expenses has historically been its investment in research and development activities.